The Role of Clinical Pharmacists in Translating Regulatory Acceptance of Biosimilars into Routine Clinical Practice

Abstract

Advances in analytical characterisation, functional assays, pharmacokinetic evaluation and manufacturing science have enabled regulatory agencies to increasingly rely on the totality of evidence, reducing the need for comparative clinical efficacy trials in scientifically justified circumstances. Consequently, the principal challenge surrounding biosimilars has shifted from demonstrating biosimilarity to ensuring their effective implementation in routine clinical practice. Despite this strong scientific consensus, variability in clinical uptake persists across healthcare systems, limited by professional uncertainty, patient concerns, organisational barriers and inadequate communication. Clinical pharmacists are uniquely positioned to bridge this gap between regulatory science and clinical implementation. This article discusses concrete strategies through which pharmacists translate regulatory confidence into clinical confidence, including interpretation of comparability evidence for prescribers, structured patient counselling to mitigate the nocebo effect and support shared decision-making, coordination of switching and traceability programmes, multidisciplinary education, and pharmacovigilance and real-world evidence generation. Their contributions across hospital, community and ambulatory care settings are explored, together with their strategic role in Pharmacy and Therapeutics Committees, procurement processes and health policy implementation. Beyond facilitating biosimilar adoption, pharmacists contribute to healthcare sustainability by promoting value-based medicine, resilient procurement strategies, responsible resource allocation and environmentally conscious pharmaceutical practices. Future opportunities, including digital pharmacovigilance, artificial intelligence and personalised implementation strategies, are also discussed. Clinical pharmacists should therefore be regarded not only as medicines experts but also as knowledge translators capable of transforming regulatory guidance into patient-centred clinical practice and sustainable healthcare delivery.